Drugs / Listerine Antiseptic Mouthwash Product
Listerine Antiseptic Mouthwash Product
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT04966507 Comparator | Feb 2022 → May 2025 | gonorrhea | University of California, Los Angeles | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Listerine Antiseptic Mouthwash Product | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04966507 ↗ |
| Known as | COOL MINT LISTERINE Antiseptic Mouthwash | “COOL MINT LISTERINE® Antiseptic Mouthwash will be used as the 'active' study drug condition.” NCT04966507 ↗ |
| Known as | Listerine Cool Mint Antiseptic Mouthwash | “Daily use of an antibacterial mouthwash (Listerine Cool Mint Antiseptic Mouthwash) during the 12-week follow-up period.” NCT04966507 ↗ |
| Action | Inhibit | “selected based on evidence demonstrating inhibitory effects of the antibacterial mouthwash (Cool Mint Listerine® Antiseptic mouthwash) against N. gonorrhoeae.” NCT04966507 ↗ |
| Route | Other | “Participants will be asked to rinse and gargle their mouth with 20mL of mouthwash daily.” NCT04966507 ↗ |